KeyBank National Association
NAVB

KeyBank National Association’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

KeyBank National Association’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,250
Closed -$83K – 1308
2014
Q1 		$83K Hold
2,250
– – ﹤0.01% 1253
2013
Q4 		$93K Buy
+2,250
New +$88K ﹤0.01% 1249

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KeyBank National Association's NAVB Position: Q2 2014 in Review

KeyBank National Association sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2014, closing a stake of 2,250 shares — an estimated $83K sold.

KeyBank National Association first reported a position in NAVB in Q4 2013 and held it in 2 quarters. The position peaked at $93K in Q4 2013. 87 funds tracked by Wall St. Rank hold NAVB as of Q2 2014.

  • KeyBank National Association reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2014 after selling out during the quarter.
  • KeyBank National Association sold 2,250 Navidea Biopharmaceuticals Inc. shares in Q2 2014, an estimated $83K.
  • KeyBank National Association first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 2 quarters.
  • KeyBank National Association's Navidea Biopharmaceuticals Inc. position peaked at $93K in Q4 2013.
  • 87 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2014.

Based on KeyBank National Association's 13F filing for Q2 2014, filed 13 Aug 2014.